Primary T-Cell Non-Hodgkin Lymphoma of the Vagina

J. L. Herraiz, 1 A. Llueca, 1 Y. Maazouzi, 1 D. Piquer, 1 A. Palmeiro, 2 and E. Calpe 1

1Department of Obstetrics and Gynecology, General University Hospital of Castellon, Avenida Benicassim S/N, Castellón de la Plana, 12004 Castelló, Spain
2Department of Pathology, General University Hospital of Castellon, Avenida Benicassim S/N, Castellón de la Plana, 12004 Castelló, Spain

Correspondence should be addressed to J. L. Herraiz; sgo.herraiz@gmail.com

Received 1 March 2015; Accepted 19 May 2015

The primary vaginal T-cell non-Hodgkin lymphoma is a rare form of lymphoma. Most of the previously published cases were about B-cell non-Hodgkin lymphomas. We present the case of a vaginal mass in an 82-year-old patient presenting vaginal bleeding. The results of the immunohistological studies of the mass revealed the presence of a cytotoxic T-cell non-Hodgkin lymphoma, which is the least common subtype.

1. Introduction

The primary affection of the female genital tract in non-Hodgkin lymphomas is rare and represents 1.5–2% of all extraganglionar primary lymphomas. The most commonly affected areas are in the ovaries (50%) and cervix, while the uterine and vaginal affection remains extremely rare (6%) [1].

The average age of onset is in the fifth decade of life [2, 3] and the most common histology is usually that of diffuse large B-cell lymphoma (DLBCL). The patient's motive for consultation is usually due to abnormal vaginal bleeding [4].

Despite the lack of standard treatments for the non-Hodgkin vaginal lymphoma, various treatment algorithms are used which include chemotherapy and radiotherapy, eliciting good results in initial stages of the disease [5].

We hereby present an unusual case of a vaginal T-cell lymphoma. Most of the reported cases were of B-cell non-Hodgkin lymphomas [1, 6].

2. Case Presentation

We present the case of an 82-year-old patient with no personal history of interest that came for a consultation in our gynecology department prompted by an episode of vaginal bleeding lasting various days. Her obstetrical/gynecological background includes 2 vaginal births and menopause at the age of 50. During the exploration, we found a mass, hard and friable in consistency, occupying the entire vaginal cavity. We biopsied the tumor, and the histologic results revealed the presence of medium-sized cells with granular nuclei and vascular destruction accompanied by necrosis. The immunohistochemistry showed CD3 (+), CD56 (−), CD8 (−), EBV (+), CD4 (+), and granzyme B (+). The studies' conclusions were that of a NK/cytotoxic T-cell extranodal lymphoma (Figures 1 and 2).

A thoracoabdominal pelvic CT scan was performed, confirming the solid mass described in our exploration: a 7.5 × 7.5 × 9 cm mass with a rounded morphology, occupying the vesical-uterine space. There were no pathological findings in the uterus and ovaries. There was no sign of retroperitoneal or pelvic lymphadenopathies, nor were there lesions at the extrapelvic level (Figure 3). The Magnetic Resonance Imaging (MRI) corroborated the findings at the vesical-uterine level, which were previously mentioned in the CT scan results (Figure 4). The PET scan showed the previously discovered mass in the vesical-uterine space, presenting a high metabolic activity (Figure 5). The rest of the studies showed no evidence of increased tumor extension. The complete blood count (CBC), LDH, B2 microglobulin, and albumin levels were within the range of normality.

The patient rejected any type of treatment. She received palliative care at home and died two months after having been diagnosed.
Figure 1: Tissue fragment where medium-sized cells and granular nucleus are observed, along with vascular destruction. The images on the left show Cdx56 (−) and EBV (+) staining.

Figure 2: Visualization of positive Epstein-Barr staining.

3. Discussion

The Lymphomas are divided into two main categories: Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). The latter is mainly currently divided into Precursor Lymphoid Neoplasms, B-cell neoplasms, and mature T/NK-Cell lymphomas. The incidence of non-Hodgkin lymphoma is 2–5% of all cancers [7].

Primary NHL manifestation in the female genital tract is extremely rare, with a prevalence ranging between 0.2 and 1.1%. Secondary affection of the genital tract due to the dissemination of a lymphoma is around 7–30% of all cases. The most frequent location in extranodal NHL cases with genital affection is the ovaries, followed by the cervix and uterus, and, lastly, the most unusual location is the vagina [8–10]. The most common histological subtype of gynecological lymphomas, primary or secondary, is the Large B-cell diffuse lymphoma [11]. The cytotoxic T-cell NHL, such as the one presented in our case, is extremely rare.

The incidence of extranodal lymphomas has increased in the last decades [4]. This increase may be justified by the association of different infectious agents, such as the Epstein-Barr virus [12], the human immunodeficiency virus [13, 14], immunosuppressive therapies [15], and exposure to toxic substances and pollutants. Additionally, this increase may be also related to the new diagnostic techniques which keep on progressing [6, 12, 16].

Figure 3: CT scan demonstrating a large mass occupying the vaginal cavity.

Figure 4: MRI demonstrating the vaginal lesion displacing the uterus towards the cranial direction.

Figure 5: PET scan showing the mass in the vesical-uterine space.
Table 1: Staging system for extranodal lymphomas. Modified Ann Arbor classification.

| Stage | Description |
|-------|-------------|
| IE    | Involvement of a single lymph node region or a single organ. |
| IIE   | Involvement of a single extralymphatic organ or site and one or more regional lymph nodes ipsilateral to diaphragm. |
| IIE   | Involvement of a single extralymphatic organ or site and regional lymph nodes on both sides of the diaphragm. |
| IVE   | Diffuse involvement or dissemination of one or more extralymphatic sites, with or without the involvement of lymphatic nodes. |

4. Conclusion

The incidence of the vaginal lymphoma is very low; however, it can demonstrate early symptoms suggesting a gynecologic neoplasm. Both gynecologist and pathologist must include this disease in the differential diagnosis of a vaginal mass so as to not delay or establish the wrong diagnosis that could lead to failure to treat these patients.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

[1] F. Lonardi, V. Ferrari, G. Pavanato, G. Bonciarelli, A. Jirillo, and M. Balli, "Primary Lymphoma of the vagina. A case report," Haematologica, vol. 79, no. 2, pp. 182–183, 1994.
[2] R. Vang, L. J. Medeiros, E. G. Silva, D. M. Gershenzon, and M. Deavers, "Non-Hodgkin's lymphoma involving the vagina: a clinicopathologic analysis of 14 patients," American Journal of Surgical Pathology, vol. 24, no. 5, pp. 719–725, 2000.
[3] S. Prevot, D. Hugol, J. Audouin et al., "Primary non-Hodgkin's malignant lymphoma of the vagina. Report of 3 cases with review of the literature," Pathology Research and Practice, vol. 188, no. 1-2, pp. 78–85, 1992.
[4] H. H. Bustos, J. Baquera, C. Robles et al., "Linfoma primario cervical no Hodgkin de células grandes con inmunofenotipo B. A propósito de un caso," Perinatologia y Reproduccion Humana, vol. 16, pp. 132–139, 2002.
[5] B. S. Marco, H. M. Fernando, and P. C. Mateo, "Quimioterapia combinada neoadyuvante seguida de radioterapia externa en el tratamiento de dos casos de linfoma primario del cuello uterino," Revista Chilena de Obstetricia y Ginecologia, vol. 70, no. 2, pp. 91–94, 2005.
[6] R. M. Bermejo, A. M. Palacios, B. Bermejo, A. Simón, and C. Díaz-Caneja, “Linfoma primario no Hodgkin difuso de células grandes B de vagina, “Progresos de Obstetricia y Ginecologia, vol. 51, no. 5, pp. 316–320, 2008.
[7] K. Butron, M. Ramirez, F. Germes, E. Ramos, and A. Zamora, "Systemic lymphoma cells with T precursor condition of extreme female genital tract. A case report and literature review," Ginecologia y Obstetricia de Mexico, vol. 77, pp. 291–299, 2009.
[8] A. D. G. Krol, S. Le Cessie, S. Snijder, J. C. Kluin-Nelemans, P. M. Kluin, and E. M. Noordijk, "Primary extranodal non-Hodgkin's lymphoma (NHL): the impact of alternative definitions tested in the Comprehensive Cancer Centre West population-based NHL registry," Annals of Oncology, vol. 14, no. 1, pp. 131–139, 2003.
[9] A. S. Lagoo and S. J. Robboy, "Lymphoma of the female genital tract: current status," International Journal of Gynecological Pathology, vol. 25, no. 1, pp. 1–21, 2006.
[10] T. R. Trenhale and M. A. Killacky, "Primary pelvic non-Hodgkin's lymphoma," Obstetrics & Gynecology, vol. 97, no. 5, part I, pp. 717–720, 2001.
[11] F. Kosari, Y. Daneshbod, R. Parwaresch, M. Krams, and H.-H. Wacker, "Lymphomas of the female genital tract: a study of 186 cases and review of the literature," The American Journal of Surgical Pathology, vol. 29, no. 11, pp. 1512–1520, 2005.
[12] S. Domingo, A. Perales, V. Torres, M. J. Alcaraz, and A. Pellicer, “Epstein-Barr virus positivity in primary vaginal lymphoma,” Gynecologic Oncology, vol. 95, no. 3, pp. 719–721, 2004.

[13] D. C. Pham, T. H. Guthrie, and B. Ndubisi, “HIV-associated primary cervical non-Hodgkin’s lymphoma and two other cases of primary pelvic non-Hodgkin’s lymphoma,” Gynecologic Oncology, vol. 90, no. 1, pp. 204–206, 2003.

[14] A. Klepfish, A. Schattner, L. Shvidel et al., “Successful treatment of aggressive HIV-associated lymphoma with combination chemotherapy, biotherapy with rituximab and HAART: presentation of a therapeutic option,” Leukemia and Lymphoma, vol. 44, no. 2, pp. 349–351, 2003.

[15] K. Yoshinaga, J.-I. Akahira, H. Niikura et al., “A case of primary mucosa-associated lymphoid tissue lymphoma of the vagina,” Human Pathology, vol. 35, no. 9, pp. 1164–1166, 2004.

[16] D. N. Lanjewar and D. D. Dongaonkar, “HIV-associated primary non-Hodgkin’s lymphoma of ovary: a case report,” Gynecologic Oncology, vol. 102, no. 3, pp. 590–592, 2006.

[17] Ö. Akbayir, K. Güngördüük, A. Gülkilik, E. Yavuz, A. İ. Tekirdağ, and E. Odabaş, “Successful treatment of primary vaginal diffuse large B-cell lymphoma using chemotherapy,” Taiwanese Journal of Obstetrics and Gynecology, vol. 47, no. 3, pp. 334–337, 2008.

[18] N. van Renterghem, P. de Paepe, R. van den Broecke, C. Bourgain, and R. Serreyn, “Primary lymphoma of the cervix uteri: a diagnostic challenge. Report of two cases and review of the literature,” European Journal of Gynaecological Oncology, vol. 26, no. 1, pp. 36–38, 2005.

[19] R. Vang, L. J. Medeiros, G. N. Fuller, A. H. Sarris, and M. Deavers, “Non-Hodgkin’s lymphoma involving the gynecologic tract: a review of 88 cases,” Advances in Anatomic Pathology, vol. 8, no. 4, pp. 200–217, 2001.

[20] A. S. Huerta, L. P. Abad, J. M. Saera, and J. Gómez-Codina, “Factores pronóstico de los linfomas óseos primarios. Importancia del Índice Pronóstico Internacional,” Oncologia, vol. 27, no. 9, pp. 55–57, 2004.

[21] E. M. Guldris N, M. P. Vázquez C, E. Carballo N, M. Porto Q, L. Heliodoro Alba O, and B. Iglesias R, “Linfoma no Hodgkin primario de vagina,” Revista Chilena de Obstetricia y Ginecologia, vol. 78, no. 1, pp. 68–71, 2013.

[22] M. Signorelli, A. Maneo, S. Cammarota et al., “Conservative management in primary genital lymphomas: the role of chemotherapy,” Gynecologic Oncology, vol. 104, no. 2, pp. 416–421, 2007.